|
Real-time Estimate
Cboe BZX
03:58:16 12/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 0.8700 USD | +10.63% |
|
-0.30% | -68.45% |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 94.96 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | -53.55% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | -71.59 | -135.9 | -67.56 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | -216.85% | -89.83% | 50.29% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -0.77x | -0.75x | -0.78x |
| PBR | - | - | - | 0.78x | 0.99x | 0.38x | 0.37x | 0.43x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0x | -0.32x | 0.18x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 457x | 312x | 382x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | -344x | -447x | -272x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | 0.57x | 0.98x | 0.47x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | 0.56x | 0.94x | 0.43x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | 0.61x | 0.97x | 0.52x |
| FCF Yield | - | - | -33.7% | 886% | -155% | 163% | 103% | 191% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.025 | -1.049 | -1.003 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.208 | 0.3043 | 0.2483 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -124.5 | -139 | -144.5 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -128.7 | -145.1 | -156.3 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -121.5 | -138.4 | -149.7 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -166.6 | -230.9 | -162.5 |
| Reference price 2 | 3.8780 | 2.4710 | 4.0200 | 3.1900 | 2.7500 | 0.7864 | 0.7864 | 0.7864 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 120,759 | - | - |
| Announcement Date | 21/9/21 | 1/5/23 | 28/3/24 | 26/3/25 | 16/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.77x | -248.69x | 0.57x | -.--% | 94.96M | |
| 17.83x | 6.86x | 13.15x | 1.67% | 68.32B | |
| 32.59x | 8.71x | 28.8x | 0.07% | 60.26B | |
| 38.31x | 6.82x | 20.38x | 0.85% | 55.86B | |
| 47.19x | 6.4x | 30.36x | -.--% | 48.43B | |
| 35.91x | 3.38x | 14.61x | -.--% | 45.34B | |
| -23.04x | 61.61x | -25.45x | -.--% | 41.76B | |
| 34.38x | 8.51x | 22.17x | 0.38% | 34.5B | |
| 41.76x | 8.19x | 27.2x | -.--% | 33.8B | |
| 30.01x | 6.36x | 16.49x | -.--% | 25.96B | |
| Average | 25.42x | -13.18x | 14.83x | 0.3% | 41B | |
| Weighted average by Cap. | 28.12x | 12.36x | 16.79x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
